Drug Trial Radar · NCT05005468
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
61
Planned (sponsor's estimate)
Start
Sep 2021
Primary completion
Aug 2023
Study completion Aug 2024
Sponsor
- Lead sponsor
- Shanghai Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse and no driver gene mutation.
Conditions
- NSCLC
Interventions
CamrelizumabDrug
Camrelizumab is given on the first day of each cycle, intravenous drip.
FamitinibDrug
Famitinib is administered orally, once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DFSTime frame: 6-18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.